LabGenius is a drug discovery company pioneering the discovery of next-generation protein therapeutics.
LabGenius leverages AI and synthetic biology to develop radically new protein materials and components.
LabGenius was founded in 2012 by James Field and is based in London, UK.
LabGenius has developed EVA - a robot scientist capable of designing, conducting, and learning from its own experiments. Importantly, the learning aspect means that EVA gets continuously smarter as it unpicks the genetic design rules that underpin life.
LabGenius' discovery platform, EVA, integrates several bleeding-edge technologies drawn from the fields of artificial intelligence, robotic automation and synthetic biology. Following discovery and characterisation, LabGenius’ proprietary molecules are taken to the clinic through pharma partnerships.
LabGenius is backed by Lux Capital, Obvious Ventures, Felicis Ventures, Inovia Capital, Acequia Capital (Acecap), Kindred Capital and others. The company raised $10M from a "Series A" financing on Oct 23, 2019. This brings LabGenius' total funding to $13.7M to date.